Introduction
Acute heart failure (AHF) represents a broad spectrum of disease states, with heterogeneous clinical presentations, but commonly characterized by either a rapid onset or a progressive worsening of signs and symptoms, requiring immediate treatment and leading to urgent hospitalization. 1 The initial clinical presentation is more heterogeneous than the simple description "de novo or worsening heart failure (HF)", and includes several distinct phenotypes such as acutely decompensated HF (DHF), cardiogenic shock (CS), pulmonary oedema (PO), right HF (RHF), hypertensive HF (HT-HF) and HF in the setting of acute coronary syndromes (ACS-HF). 2 In addition to clinical profile classification, several other classification schemes have been proposed by the European Society of Cardiology (ESC) guidelines, including classification based on the level of systolic blood pressure (SBP) at initial presentation in the emergency department 3 and the most recent one with phenotypes based on clinical signs of congestion and/or hypoperfusion. 1 The identification of more distinct entities with different clinical outcomes would help clinicians to address the immediate life-threatening medical condition and to direct treatment strategies more correctly by targeting specific underlying conditions and precipitating factors, 4 in order to create pathways for better care of the spectrum of AHF patients.
Several large and well designed registries 5 -12 have been created in recent years to describe more accurately the demographic, clinical, and therapeutic characteristics of AHF patients. However, with very few exceptions, 12,13 the description of the clinical course of AHF from prior registries was mainly restricted to the inpatient phase or the initial weeks post-discharge. Very often, these registries were not representative, being either a single country description, or having a limited number of centres or clinical settings.
The ESC Heart Failure Long-Term (ESC-HF-LT) Registry is a permanent registry 14, 15 with systematic collection of 1-year follow-up data, capturing the whole spectrum of AHF patients.
The aim of the present analysis of the ESC-HF-LT Registry was to identify differences in clinical characteristics, in-hospital treatment and outcomes among AHF patients stratified according to well specified clinical profiles within the overall descriptor of AHF. 
Methods

Study design and clinical setting
The ESC-HF-LT Registry is a prospective, multicentre, observational study of patients admitted to 211 cardiology centres (Appendix S1) from 21 European and Mediterranean countries, all members of the ESC. The number of participating centres per country was chosen in relation to the population of the country (one centre/2 million people, but no more than 25 centres per country) and centre selection took into account the geographical distribution of each country. Moreover, the selection of centres allowed for a representation of each category of hospitals and hospital facilities according to the distribution of the different types of medical centres in the individual country, approximately 20% of which should consist of centres providing cardiac surgery, 30% that do not provide cardiac surgery but do provide . interventional cardiology, and 50% community centres providing neither cardiac surgery nor interventional cardiology.
Periodic consecutive enrollment has been used and patients were included 'one day per week'. In this 1-year follow-up analysis, patient data of the best 12 consecutive recruitment months for each country were used for the analysis.
The survey was approved by each local Institutional Review Board according to the rules of each participating country. No data were collected before detailed information was provided to the patient and a signed informed consent was obtained.
The EURObservational Research Programme (EORP) Department was appointed to coordinate the project operationally, providing support to the committees, national coordinators and participating centres, and overseeing the implementation of the survey.
Patient population
The ESC-HF-LT Registry included all outpatients with chronic HF seen at the clinics and those admitted to hospital for AHF from selected centres. In the present analysis, all patients admitted for AHF, either de novo, or worsening of pre-existing HF, for whom intravenous (i.v.) therapy (inotropes, vasodilators, or diuretics) was needed, were included. There were no specific exclusion criteria, with the exception that all patients had to be older than 18 years.
A diagnosis of AHF was made by the clinician-investigators at initial presentation and required the presence of signs and symptoms of HF, evidence of cardiac dysfunction, and the need for i.v. therapy. 14, 15 Several training meetings were organized for the study investigators to assure consistency in definition and data collection, and for a random sample of 5% of centres, data source verification was performed by EORP monitors.
Patients were classified into the following six clinical profiles by the clinician-investigators at the time of presentation according to the 2008 ESC guidelines: 2 DHF, CS, PO, RHF, HT-HF and ACS-HF (see Supplementary material online, Appendix S2). Another two classifications, including SBP at presentation (<85 mmHg, 85-110 mmHg, 110-140 mmHg and >140 mmHg) 3 and a classification based on the presence of clinical signs of congestion and/or hypoperfusion (no congestion and no hypoperfusion; congestion without hypoperfusion; hypoperfusion without congestion; hypoperfusion and congestion) 1 were used for reporting in-hospital and 1-year adverse outcomes.
A follow-up visit 12 months after the entry visit was used to collect information on morbidity and mortality.
Data collection
All data including demographics, medical history, clinical presentation, laboratory results, inpatient management and in-hospital and 1-year outcomes were collected by chart review and entered into a centrally managed online database using a web-based electronic case report form. Automated electronic data checks were performed to prevent out-of-range or duplicate entries.
In-hospital outcome included all-cause mortality. One-year outcomes included 1-year mortality, 1-year HF readmissions and 1-year death or HF readmission. The cause of death was categorized as cardiac, vascular, non-cardiovascular, and unknown. 16 Figure 1 Classification of acute heart failure patients by geographical area. A: clinical profile classification by geographical area. B: systolic blood pressure (SBP) classification by geographical area. C: congestion/hypoperfusion classification by geographical area. ACS-HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; HT-HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure.
non-parametric test (Kruskal-Wallis test). Categorical variables were reported as percentages and compared using chi-square test or Fisher's exact test if any expected cell count was less than 5. For categorical variables with more than two possible values, exact P-values were estimated according to the Monte Carlo method. Univariable analysis was applied to both continuous and categorical variables.
Baseline characteristics and type of treatments were reported by clinical profile classification. In-hospital and 1-year post-discharge outcomes were also reported stratified by clinical profile, SBP classification and congestion/hypoperfusion. Plots of the Kaplan-Meier curves for time to all-cause death, time to HF hospitalization and time to all-cause death or HF hospitalization were performed for each clinical profile and for each SBP category. In addition to unadjusted Kaplan-Meier curves, Cox proportional hazard models with multivariable adjustment by clinical relevant variables such age, gender, chronic kidney disease, chronic obstructive pulmonary disease and cancer, have been performed. outcomes in each group were compared using log-rank test. A Tukey's adjustment of log-rank has been performed and all clinical profiles and SBP categories were pairwise compared for each time point and each outcome.
A two-sided P-value of <0.05 was considered statistically significant. All analyses were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
From April 2011 to June 2015, 16 012 patients were enrolled in the ESC-HF-LT Registry. Of these, 6629 patients (41.4% of the total database) were hospitalized with a primary diagnosis of AHF and 9383 patients (58.6%) were ambulatory patients with chronic HF. At 1 year, 411 AHF patients were lost to follow up, representing 6.2% of the study population. Median follow-up time was 378 (288-415) days.
Clinical classifications
Of the AHF patients enrolled in the registry, 13.2% presented with PO, 2.9% with CS, 61.1% with DHF, 4.8% with HT-HF, 3.5% with RHF, and 14.4% with ACS-HF.
The variation in classifications by geographical area is depicted in Figure 1 . Considering SBP classification, 1.9% of AHF patients presented with SBP <85 mmHg, 24.9% with SBP 85-110 mmHg, 42.9% with SBP 110-140 mmHg, and 30.3% with SBP >140 mmHg. Phenotyping AHF patients by clinical signs of congestion/hypoperfusion showed four mutually exclusive categories: no congestion and no hypoperfusion (14.8%), congestion without hypoperfusion (69.7%), congestion and hypoperfusion (13.6%), and hypoperfusion without congestion (0.9%) (Figure 1 ).
Baseline characteristics and clinical profiles on admission
The group with PO had the highest proportion of patients older than 75 years, while the proportion of females was highest in RHF, HT-HF and PO ( Table 1) .
Ischaemic aetiology was common in patients with CS (68.2%), while valvular aetiology was most frequent in RHF patients (27.0%). Large variations in reported aetiologies were noted in patients admitted with DHF ( Table 1) . Patients admitted with HT-HF and ACS-HF had fewer co-morbidities than patients with CS and RHF ( Table 1) .
At presentation, SBP differed markedly among clinical profiles and varied from 101.9 ± 29 mmHg in CS patients to 168.3 ± 31 mmHg in HT-HF patients. Patients with CS retained distinguishing clinical features in terms of low SBP and signs of hypoperfusion, while most of the clinical characteristics were similar in patients with PO and DHF. Patients presenting with RHF had a constellation of clinical signs, including jugular venous pressure >6, peripheral oedema and hepatomegaly.
Haemoglobin level <12 g/dL was found in 39% of patients and was more frequently observed in patients admitted with RHF and CS. A significantly higher proportion of CS patients presented with baseline renal dysfunction (creatinine >1.5 mg/dL). Hyperglycaemia (blood glucose >120 mg/dL) at presentation was reported in 41% of patients and in more than half of patients admitted with PO, CS and ACS-HF ( Table 1) .
A more elevated level of natriuretic peptides was found in patients with CS and PO compared with other clinical profiles. High troponin levels on admission were a distinctive feature of patients with ACS-HF and were also common in patients with CS and PO ( Table 1) .
The proportion of patients with atrial fibrillation (AF) varied widely between the clinical profiles, with the highest AF prevalence being documented in patients with RHF. A proportion of 26% of patients had QRS duration >120 ms. QRS duration was larger in patients with CS and DHF, and the prevalence of left bundle branch block was highest in PO patients. Particularly, for patients admitted with CS, a longer QT interval duration was noted ( 
In-hospital management
The use of i.v. treatments and interventional procedures in the different clinical profiles are reported in Table 2 . In clinical profiles consistent with more severe HF, such as CS and PO, coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) and intra-aortic balloon pump insertion were more frequently used.
In-hospital outcomes
The highest rate of in-hospital all-cause mortality was noted in CS patients (36.1%) and the lowest in HT-HF patients (1.8%) ( Table 3) . When patients were stratified by SBP at admission, the highest in-hospital mortality was observed in patients with SBP <85 mmHg (26.6%) and the lowest in patients with SBP >140 mmHg (2.7%). Considering the congestion/hypoperfusion classification, the highest mortality was noted in patients with presence of both congestion and hypoperfusion signs (16.5%) and lowest in patients without congestion and without hypoperfusion (1.7%). Most of the in-hospital deaths were cardiac in origin.
For patients hospitalized with CS, of the total number of deaths during hospitalization, 49% occurred in the first 24 hours from presentation, while for patients with PO, 16.3% of deaths occurred in the first 24 hours. For the remaining clinical profiles, the rate of death in the first 24 hours represented less than 10% of total number of deaths occurring during hospitalization.
Between admission and discharge, New York Heart Association (NYHA) class and clinical signs and symptoms suggestive of HF showed substantial variation ( Figure 2) .
Of patients discharged alive, worsening renal function was documented in 12.5% of patients, and it was reported more often in patients hospitalized for CS (21.0%). Patients classified as CS and RHF had more frequent hyponatraemia at discharge as compared with other clinical profiles ( Table 3) .
One-year outcomes
One-year mortality rate was 26.7% and 1-year HF hospitalization was 25.9% (Table 4) . Cardiovascular deaths represented 57.2% of total deaths in the overall population. Similar to in-hospital mortality, the highest 1-year mortality rate was observed in patients with CS (54.0%), low SBP at admission (34.8%) and in patients with both congestion and hypoperfusion (29.8%) . Figures 3 and 4 show the Kaplan-Meier curves for all-cause mortality, and the combined event of all-cause mortality and HF hospitalization for AHF patients stratified by clinical profiles, at different time points (at admission, and 1, 3, 6 and 12 months post-discharge). One-year outcome rates of each clinical profile ACS-HF, acute heart failure and associated acute coronary syndromes; AF, atrial fibrillation; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CS, cardiogenic shock; DHF, decompensated heart failure; EF, ejection fraction; HR, heart rate; HT-HF, hypertensive heart failure; HTN, hypertension; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; JVP, jugular venous pressure; LBBB, left bundle branch block; MI, myocardial infarction; NT-proBNP, N-terminal proBNP; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PM, pacemaker; PO, pulmonary oedema; RHF, right heart failure; SBP, systolic blood pressure; VTE, venous thromboembolism; TIA, transient ischemic attack. ACS-HF, acute heart failure and associated acute coronary syndromes; CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; CS, cardiogenic shock; DHF, decompensated heart failure; EPS, electrophysiological study; HT-HF, hypertensive heart failure; IABP, intra-aortic balloon pump; ICD, implantable cardioverter-defibrillator; PO, pulmonary oedema; RHF, right heart failure. * CRT-D, CRT-P and ICD are mutually exclusive terms.
Table 2 Intravenous vasoactive therapies and interventions during hospitalization
have been pairwise compared for each outcome at each time point (see Supplementary material online, Table S1 ). Adjusted Cox proportional hazard models for each outcome are presented in the Supplementary material online, ACS-HF, acute heart failure and associated acute coronary syndromes; BNP, brain natriuretic peptide; CS, cardiogenic shock; DHF, decompensated heart failure; HT-HF, hypertensive heart failure; IQR, interquartile range; NT-proBNP, N-terminal proBNP; NYHA, New York Heart Association; PO, pulmonary oedema; RHF, right heart failure; WRF, worsening renal function. * Serum creatinine difference between hospitalization and discharge >0.3.
all-cause mortality between PO, DHF, RHF and CS patients, even from 1-month post-discharge (see Supplementary material online, Figure S1 ). A similar analysis has been performed for SBP categories (see Supplementary material online, Figures S2 and S3) , showing that between 6 and 12 months post-discharge there were no significant differences in subsequent 1-year mortality among the four SBP categories.
For 1-year HF hospitalization, 6-month post-discharge analysis showed reduced differences among clinical profiles and SBP groups, and at 1-year post-discharge there were no differences in outcomes among all clinical profiles and SBP groups.
Discussion
The present analysis describes the classification of patients with AHF, covering the entire spectrum of patients with AHF. Classification of AHF patients may facilitate an early decision-making regarding appropriate triage and targeted treatment of high-risk populations.
Although DHF was the most common clinical presentation, similar to other registries, 6 -10,14 considerable differences in the prevalence of clinical profiles have been found across geographical regions. Furthermore, when considering other classification schemes, such as the most recent one based on congestion and hypoperfusion, substantial geographical variability has been found. The explanations for these geographical differences may be 'investigator-related' and 'system-related'. challenging. Similar to other studies, 17, 18 an elevated SBP at admission and signs of pulmonary congestion are common findings at presentation in PO, DHF and HT-HF patients, leading to misclassification and overlap between these AHF phenotypes.
Patients with CS were significantly different from the other clinical profiles for all clinical characteristics and should therefore be considered separately. 19 In CS patients, overall utilization of i.v. inotropes during hospitalization (81.0%) exceeds the proportion of patients presenting with hypoperfusion signs at admission (56.4%). However, clinical signs vary rapidly during presentation 20 and for some CS patients, hypoperfusion signs may not be apparent at presentation and become manifest later during hospitalization, suggesting ongoing clinical worsening despite the use of initial therapies.
Right HF was also distinguishable from the other scenarios in terms of clinical characteristics and high 1-year readmissions (48.3%). The clinical picture is dominated by signs of systemic congestion (jugular venous pressure >6, peripheral oedema and hepatomegaly) resulting from impaired right ventricular ACS-HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; HT-HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure.
filling and/or reduced right ventricular output. 21 Furthermore, patients with RHF have many co-morbidities, which may prevent the optimization of HF evidence-based therapies. Addressing non-cardiac co-morbidities may be particularly important, since a vast proportion of re-hospitalizations are not HF-related.
The ESC-HF-LT Registry is one of the few registries to describe AHF in the setting of ACS, and its reported prevalence of 14.4% was similar to that found in the Italian IN-HF Outcome registry. 9 ACS-HF patients present with clinical signs indicative of high left ventricular filling pressures (pulmonary rales, S3 sound, mitral regurgitation murmur) suggesting the impact of acute ischaemia on diastolic and systolic properties of the left ventricle.
The prevalence of moderate-to-severe mitral and tricuspid regurgitation is similar to that reported in previous registries.
12 Different from chronic settings, the prevalence of mitral and tricuspid regurgitation may be overestimated in AHF. During hospitalization, the severity of functional regurgitation may decrease as a result of decongestive therapies.
In-hospital management
The type and proportions of vasoactive medications, stratified by clinical profile, are similar to those reported by other contemporary registries, 5 Registry shows a lower use of i.v. inotropes in non-CS patients compared to previous registries. Although ischaemic heart disease is by far the most common aetiology of AHF, coronary angiography and PCI/CABG were performed only in 21% and 10% of patients. Furthermore, even in patients classified as ACS-HF, coronary angiography and PCI/CABG were performed in 45.9% and 33.9% of patients, suggesting large variations in available facilities, 22 as well as variations in guideline adherence across the participating centres.
The proportion of patients with cardiac resynchronization therapy/cardioverter-defibrillator implants is similar to other studies. 22 Although guidelines do not recommend to implant devices during acute decompensation, several patients may derive benefit from in-hospital screening targeting device implantation during hospitalization. Further research is necessary to clarify the optimal timing of device implantation during hospitalization or soon after discharge among AHF patients.
In-hospital outcomes
The highest mortality rates were observed in patients with CS, in those with SBP <85 mmHg, and in patients presenting with both congestion and hypoperfusion signs. Notably, in-hospital and 1-year mortality in CS were higher than in the group with SBP <85 mmHg ACS-HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; HF, heart failure; HT-HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure; SBP, systolic blood pressure.
or in the group with both congestion and hypoperfusion signs, suggesting that general metabolic compromise and multi-organ failure, characteristic of CS, have distinct pathways beyond SBP and hypoperfusion, and may be responsible for the excess mortality. For patients admitted with CS, 49% of in-hospital deaths occurred in the first 24 hours from presentation, suggesting that early identification of hypoperfusion signs, as well as . Figure 3 Kaplan-Meier curves for all-cause death at different time points: at admission (A), and at 1, 3, 6, and 12 months post-discharge (B). ACS-HF, acute heart failure and associated acute coronary syndromes; CS, cardiogenic shock; DHF, decompensated heart failure; HT-HF, hypertensive heart failure; PO, pulmonary oedema; RHF, right heart failure.
One-year outcomes
Similar to previous registries, 25 -28 1-year outcome rates of each clinical profile considered by the ESC-HF-LT Registry remain unacceptably high, confirming that hospitalization for AHF represents a change in the trajectory of the disease process. This finding can be explained by the fact that in-hospital therapeutic approaches to these patients have remained practically unchanged during the last few decades.
In the ESC-HF-LT Registry, the proportion of cardiovascular deaths (57.5%) is lower than in the ESC-HF Pilot study (66%) and lower than in the Italian IN-HF Outcome registry (71%).
Present data reveal that 20% of patients are discharged despite persistent signs and symptoms of HF. A negligible decrease or an increase in body weight suggest a possible failure to relieve clinical congestion during index hospitalization, which may potentially contribute to the high post-discharge event rate in the registry. Furthermore, for some AHF patients, natriuretic peptide levels do not decrease, or decrease insufficiently during hospitalization. Although the complete mechanisms are unknown, an insufficient decrease or re-elevation of natriuretic peptides during hospitalization suggests residual haemodynamic congestion as a result of suboptimal treatment. The highest rate of 1-year death was observed in patients admitted with CS, and the highest rate of 1-year HF re-hospitalization was noted in patients with RHF. Patients with HT-HF and ACS-HF had the best survival during hospitalization and throughout the follow-up. These patients presented with high or normal SBP, had a lower index of non-cardiac co-morbidities, and were discharged with minimal residual congestion, better NYHA class and better renal function when compared to other clinical profiles. Furthermore, identification of aetiological factors and precipitants, as well as aetiological treatment (coronary interventions or hypertension treatment) is easier in these two clinical profiles.
Differences in 1-year outcome among clinical profiles and SBP categories depend on the time of the analysis. In particular, when performed later after discharge, differences in outcome rates among clinical profiles tend to disappear, and all clinical profiles have comparable 1-year outcomes between 6 and 12 months post-discharge. ACS-HF and HT-HF patients tend to equalize 1-year mortality rate of CS patients after 6 months post-discharge. A similar finding was found when 1-year outcomes were compared among SBP categories, and after 6 months post-discharge, no differences in 1-year outcome were noted. This finding can be relevant for future clinical trials enrolling patients hospitalized for AHF at different time intervals
Survival probability
Time between admission and death/readmission /last visit Figure S1 . Kaplan-Meier survival curves for all-cause death (excluding patients with ACS-HF and HT-HF) at admission, and at 1, 3, 6 and 12 months post-discharge. Figure S2 . Kaplan-Meier survival curves for all-cause death for SBP categories at admission, and at 1, 3, 6 and 12 months post-discharge. Figure S3 . Kaplan-Meier curves for all-cause death and HF hospitalization for SBP categories at admission, and at 1, 3, 6 and 12 months post-discharge.
